The ARL6IP1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated in the near-haploid HAP1 cell line. This product provides a pool of cells with targeted disruption of the ARL6IP1 gene, enabling loss-of-function studies without the need for single-cell cloning. The polyclonal format captures the genetic heterogeneity of the knockout population, making it suitable for pooled functional assays and high-throughput screening applications.
HAP1 cells are a human near-haploid cell line derived from the chronic myeloid leukemia cell line KBM-7. These cells exhibit a fibroblast-like adherent morphology and maintain a largely haploid karyotype, except for a single chromosomal fragment containing a heterozygous region. The near-haploid genome simplifies genetic manipulation and phenotypic analysis by eliminating the complexity of diploid gene copies, making HAP1 cells a powerful platform for CRISPR-based knockout studies, genetic screens, and drug target validation.
ARL6IP1 encodes an endoplasmic reticulum (ER)-shaping protein that cooperates with the GTPase ATL1 and the reticulon family member RTN4 to promote ER tubule formation and maintenance. ARL6IP1 interacts with additional ER morphogenesis factors, including REEP3 and REEP4, and its function is regulated by upstream ER stress signals involving ATF6 and XBP1. Disruption of ARL6IP1 impairs ER tubule network architecture, alters ATL1-mediated ER fusion, and enhances susceptibility to ER stress-induced apoptosis, thereby highlighting its role in coordinating ER dynamics with cellular stress responses.
In the HAP1 cell context, ARL6IP1 knockout provides a clean genetic background for dissecting ER morphology pathways. The near-haploid nature of HAP1 cells ensures that knockout phenotypes are not masked by a second allele, allowing clear interpretation of ER structure-function relationships. This model is particularly relevant for studying the molecular pathogenesis of hereditary spastic paraplegia 61 (SPG61), a neurodegenerative disorder linked to ARL6IP1 mutations, and for investigating how ER shaping proteins contribute to neuronal health.
Researchers can employ these polyclonal knockout cells in a range of assays, including immunofluorescence staining for ER markers such as calnexin and KDEL to visualize ER morphology changes, western blotting for ER stress markers like BiP and CHOP, and confocal microscopy-based ER tubule analysis. Co-immunoprecipitation experiments can probe ATL1 interactions, while RT-qPCR can monitor unfolded protein response (UPR) target gene expression. These cells are also suitable for cell viability assays under ER stress conditions and for drug screening campaigns targeting ER-related neurodegenerative pathways. For further technical details, please contact Ascent Research.
